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Objective. To assess the Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) with respect
to its selection and weighting of items.
Methods. This study used the BVAS/WG data from the Wegener’s Granulomatosis Etanercept Trial. The scoring fre-
quencies of the 34 predefined items and any “other” items added by clinicians were calculated. Using linear regression
with generalized estimating equations in which the physician global assessment (PGA) of disease activity was the
dependent variable, we computed weights for all predefined items. We also created variables for clinical manifestations
frequently added as other items, and computed weights for these as well. We searched for the model that included the
items and their generated weights yielding an activity score with the highest R2 to predict the PGA.
Results. We analyzed 2,044 BVAS/WG assessments from 180 patients; 734 assessments were scored during active disease.
The highest R2 with the PGA was obtained by scoring WG activity based on the following items: the 25 predefined items
rated on >5 visits, the 2 newly created fatigue and weight loss variables, the remaining minor other and major other items,
and a variable that signified whether new or worse items were present at a specific visit. The weights assigned to the items
ranged from 1 to 21. Compared with the original BVAS/WG, this modified score correlated significantly more strongly
with the PGA.
Conclusion. This study suggests possibilities to enhance the item selection and weighting of the BVAS/WG. These changes
may increase this instrument’s ability to capture the continuum of disease activity in WG.
INTRODUCTION
The Birmingham Vasculitis Activity Score for Wegener’s
Granulomatosis (BVAS/WG) is an instrument designed to
measure disease activity (1) and has been used to describe
patient populations and to assess treatment efficacy in
clinical trials. Much in the same manner as the instrument
from which it was derived, the Birmingham Vasculitis
Activity Score (BVAS) (2), the BVAS/WG computes dis-
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organ system manifestations caused by active Wegener’s
granulomatosis (WG). Such manifestations are collated in
a list of 34 predefined items, whereas other unlisted clin-
ical features can be added manually by the clinician. Items
carry weights of either 1 or 3 that reflect differences in
terms of severity.
The BVAS/WG has been validated for clinical use (1),
but still has potential limitations (3). The comprehensive-
ness of the 34-item list has not been verified in a clinical
setting, and it is possible that it does not include all items
most relevant to active WG. Moreover, the weights of 1 or
3 were determined empirically, by expert opinion, and
they may not accurately reflect the relative disease activity
of these manifestations. Finally, the importance, if any, of
distinguishing between new/worse as opposed to persis-
tent disease activity remains unclear. Although these po-
tential limitations of the BVAS/WG do not affect the in-
strument’s performance in dichotomizing WG into disease
that is either active or inactive, they do call into question
the use of the BVAS/WG as a continuous measure.
To address these matters, we reevaluated the BVAS/WG
item selection and weighting based on the data collected
in a large clinical trial that used this instrument as the
primary outcome measurement tool.
MATERIALS AND METHODS
Study setting. The Wegener’s Granulomatosis Etaner-
cept Trial (WGET) evaluated the investigational medica-
tion plus standard care in the induction and maintenance
of disease remissions (4). Members of the WGET Research
Group are listed in Appendix A. This randomized, double-
blind, placebo-controlled trial enrolled 180 patients from 8
centers in the US. Eligibility criteria included newly diag-
nosed or flaring WG with a baseline disease activity level
of 3 according to the BVAS/WG. We analyzed data on all
BVAS/WG forms collected for every patient throughout
the trial. This included assessments at baseline, 6 weeks,
and 12 weeks, then every 3 months until the common
study closeout date, and 3 and 6 months thereafter.
BVAS/WG instrument. The BVAS/WG instrument is a
1-page form comprising 34 predefined items grouped into
9 organ systems. The items included refer to clinical fea-
tures frequently observed in patients with active WG. For
example, the pulmonary system items include pleurisy,
nodules or cavities, other infiltrate secondary to WG, en-
dobronchial involvement, alveolar hemorrhage, and respi-
ratory failure. Each item has a specified weight of either
3 or 1, depending on whether it reflects major or minor
disease activity. Manifestations detected by the clinician
but not listed as original items can be added in a free-text
section entitled “other.” Other items are also weighted
either 3 or 1 based on the rater’s judgment.
The total BVAS/WG score is the weighted sum of indi-
vidual manifestations that are present and believed to be
due to active WG. Higher scores reflect more active dis-
ease. BVAS/WG scores range from 0 to 64, not including
possible other items. Reported items are categorized fur-
ther as new/worse (i.e., new occurrence or worsening dur-
ing the previous 28 days) or persistent (i.e., continued
presence without worsening since the last assessment), but
both categories contribute equally to the final BVAS/WG
score. The BVAS/WG also includes a physician’s global
assessment (PGA) that consists of an undivided 100-mm
visual analog scale anchored by remission (score 0) and
maximum activity (score 100). The result of the PGA is not
included in the BVAS/WG score (1).
Evaluation of BVAS/WG item use. To determine which
clinical features are most relevant to the assessment of
disease activity in WG, we calculated the frequency of use
of the BVAS/WG items and of the various manifestations
added as other. Frequencies were calculated per patient
(i.e., proportion of patients in which a given item was
rated at least once) and per visit (i.e., proportion of trial
visits in which a given item was rated). We also evaluated
the frequency with which items were categorized as new/
worse or persistent.
Generation of data-driven weights for BVAS/WG items
and newly derived variables and cross-validation. Data-
driven weights for the BVAS/WG items were generated by
multiple linear regression that used the PGA values of
disease activity as the dependent variable and the individ-
ual BVAS/WG items as explanatory variables. Generalized
estimating equation (GEE) techniques were used to ac-
count for the possibility that measurements were corre-
lated with each other (5). In all primary analyses, the data
were clustered by patients, but we also performed second-
ary analyses accounting for potential clustering of data
from any one trial center. The new item weights were
assigned based on the beta regression coefficients, rounded
to the nearest integer (6). If a given model generated neg-
ative regression coefficients for 1 or several explanatory
variables, we removed those terms one by one according to
a stepwise backward procedure (by eliminating the one
with the lowest value) until all of the remaining variables
had regression coefficients 0.
To exclude from the model explanatory variables un-
likely to produce reliable estimates, we included only
those of the 34 predefined BVAS/WG items that had been
recorded at 5 visits. Predefined items rated at 1–4 visits
were merged with the major other or minor other items,
according to whether the weight initially assigned to them
was 3 or 1. Subsequently, among the list of recorded other
items, we created new specific items for those clinical
features that had been added at 10 visits. Finally, to
assess the impact of new or worse disease (as compared
with persistent disease), we defined a new/worse variable
that was set to 0 for visits with no item rated as new/worse
and to a nonzero value (with various coding formats
tested) for visits with 1 item rated as new/worse. These
supplementary items were entered one by one as explan-
atory variables to the regression model and were retained
only if they improved the model’s fit to the data.
To evaluate a model’s fit to the data, we calculated
preliminary activity scores for all trial visits. These scores
were based on the precise items included in a given model
and the weights produced by the model. The square of
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Pearson’s correlation coefficient (R2) was used to evaluate
a score’s ability to explain the PGA. The model ultimately
retained was determined as that with the highest R2.
Cross-validation was performed to evaluate the replica-
bility of the linear regression model (7,8). The full data set
was split into several subsets using 2 distinct approaches.
In the first approach, we randomly split the entire data set
into 5 subsets of equal size; to ensure that all subgroups
were composed of visits displaying a similar range of
disease activity levels, each subgroup was assembled by
randomly selecting one-fifth of the baseline visits and one-
fifth of the nonbaseline visits. In the second approach, the
data set was divided according to trial centers; the data of
2 centers with the lowest enrollments were merged to
reduce the differences in subset sizes. For both data parti-
tioning approaches, the linear regression analyses (which
included the same explanatory variables as those retained
in the best-fitting model obtained from the full data set)
were repeated by omitting 1 subset of the data at a time.
The item weights generated by these derivation models
were again equated with the beta coefficients rounded to
the nearest integer, but, in order to adopt the most conser-
vative approach, items could also be assigned negative
weights. By applying these weighting systems to their
corresponding validation subgroups that consisted of vis-
its excluded from the regression model, we recalculated
activity scores and computed their R2 value to predict the
PGA. We interpreted significant reductions in the R2 value
(compared with that obtained from the full data set) as an
indication of poor replicability.
For all models, assumptions of linearity were checked
graphically by drawing plots of the observed values versus
the predicted values, and of the residuals versus predicted
values.
Evaluation of the validity of data-driven item weights
and modified item selection. To assess the validity of the
changes in item selection and weights, we compared the
activity scores obtained by this modified BVAS/WG in-
strument with the BVAS/WG as originally described. We
also compared the modified instrument with a completely
unweighted BVAS/WG in which all items were empiri-
cally assigned a weight of 1. For all 3 variations of the
BVAS/WG instrument, we assessed Pearson’s correlation
coefficients (r) with the PGA. Hotelling’s statistics were
used to determine whether the differences between 2 de-
pendent correlations were statistically significant (9).
Comparisons were made within the full data set, within
the subset of visits in which WG was active, and within the
baseline visits alone. In addition, we performed subgroup
analyses based on whether the patients had severe or lim-
ited WG at trial entry (10).
Statistical analyses. All statistics were computed by the
SAS Statistical Software, version 9.1 for Windows (SAS
Institute, Cary, NC). For all analyses, a 2-tailed P value less
than 0.05 was considered significant. Continuous variables
were expressed as the mean  SD and range.
RESULTS
WGET data set and data checking. The 180 WGET par-
ticipants contributed 2,044 trial visits. The mean  SD
followup (from baseline to last visit) was 30.3  11.7
months (range 0–47.0). The mean number of visits per
patient was 11.4  3.8 (range 1–17).
Among the 2,044 BVAS/WG forms analyzed, we reclas-
sified 20 manifestations listed as other items into their
appropriate original item designation (for example, orbital
pseudotumor and biopsy-proven glomerulonephritis were
reclassified as one of the original items: retroorbital mass/
proptosis and red cell casts, respectively). Data checking
also identified 8 forms in which both hematuria and red
cell casts were scored. For those visits, we analyzed only
red cell casts, according to the original BVAS/WG provi-
sions (1).
For 1 visit, the BVAS/WG form was incomplete, and 17
forms had missing PGA values. None of these 18 BVAS/
WG forms (0.9%) occurred at a baseline visit. Among the
2,026 BVAS/WG forms with no missing data, we defined
734 as representing active disease because the PGA score
was 0. Among those 734 forms, 21 had BVAS/WG scores
of 0, including 4 with possible outlying PGA values of 11,
21, 34, and 80, respectively (all occurring during followup
visits). Among the 1,292 forms with PGA scores of 0, there
were only 9 for which the BVAS/WG score was not 0
(range 1–4).
Use of predefined original and other BVAS/WG items.
Item use was calculated from all 2,044 BVAS/WG forms.
The frequency of use of each individual original item is
shown in Table 1. Five predefined items were reported in
only 1–4 forms (respiratory failure, pericarditis, mesen-
teric ischemia, gangrene, and uveitis), and 4 items were
never utilized (retinal exudates/hemorrhage, meningitis,
cord lesion, and stroke). Table 1 also shows the proportion
of study patients for whom each individual item had been
rated during at least 1 visit.
A total of 175 other items were added at 149 visits,
including 18 rated as major and 157 rated as minor. The
most commonly added other item was fatigue, rated in 58
forms; fatigue was rated as the only manifestation in 6
followup visits (corresponding to 3 different subjects).
Weight loss was added to 12 visits and was never rated in
isolation. The entire list of other manifestations is shown
in Table 2. To simplify the presentation, other items were
combined, when appropriate, under generic headings.
New/worse and persistent status of items scored. Of the
total 1,855 ratings of predefined items, 568 (31%) were
classified as persistent and 1,287 (69%) were classified as
new/worse. Among the 175 other items, 40 (23%) were
classified as persistent, and 135 (77%) as new/worse. In
total, 447 (22%) and 305 (15%) BVAS/WG forms had 1
and 2 items checked as new/worse, respectively. At the
baseline visits, 829 (95%) and 47 (5%) of the rated items
were new/worse and persistent, respectively, and 1 and
2 new/worse items were reported for 175 (97%) and 168
(93%) patients, respectively.
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Data-driven BVAS/WG item weighting. Linear regres-
sion models were based on the 734 complete BVAS/WG
forms with active disease. Similar results were obtained
when these analyses used all 2,026 complete BVAS/WG
forms, because the differences between the samples mostly
included noninformative visits with 0 values for both
BVAS/WG score and PGA.
A flow diagram of explanatory variables implemented in
the linear regression models is shown in Figure 1. The
initial linear model included the 25 predefined BVAS/WG
items rated in 5 forms, the major other variable, and the
minor other variable. Using the weights produced by this
model, we calculated the activity scores and their ability
(R2) to explain the PGA. As compared with the R2 value of
0.5693 for the original BVAS/WG (and the R2 value of
0.5278 for the unweighted BVAS/WG), the R2 value for
this preliminary index was 0.6248. The introduction of the
variables fatigue and weight loss into this model improved
the R2 to 0.6275 and 0.6310, respectively. Additional spe-
cific variables were also created for skin nodules and oti-
tis/mastoiditis, but insertion of these variables into the
model either did not further improve the model’s ability to
explain the PGA (R2  0.6310) or yielded a negative beta
regression coefficient (1.3181, P  0.4651). Thus, these
latter 2 variables were not retained in the models.
We then added a new/worse variable, based upon
whether 1 items present at a given visit were classified as
either new or worse. We analyzed several formats for this
variable, and obtained the following R2 values: ordinal
(exact number of new/worse items at visit): R2  0.6510;
dichotomous (0 or 1 new/worse items at visit): R2 
Table 2. Use of other Birmingham Vasculitis Activity
Score for Wegener’s Granulomatosis items in 180









All combined 175 (8.6) 84 (46.7)
Fatigue 58 (2.8) 28 (15.6)
Weight loss 12 (0.6) 12 (6.7)
Skin nodules 12 (0.6) 10 (5.6)
Otitis/mastoiditis 11 (0.5) 7 (3.9)
Chondritis 8 (0.4) 5 (2.8)
Miscellaneous skin items† 7 (0.3) 6 (3.3)
Myositis/myalgia 5 (0.2) 5 (2.8)
Respiratory items† 5 (0.2) 5 (2.8)
Optic neuritis‡ 5 (0.2) 2 (1.1)
Eye adnexa disease-related
items†
5 (0.2) 4 (2.2)
Laryngotracheal items§ 5 (0.2) 4 (2.2)
Rash 5 (0.2) 2 (1.1)
Breast involvement 5 (0.2) 1 (0.6)
Proteinuria 4 (0.2) 4 (2.2)
Gingivitis 3 (0.1) 3 (1.7)
CNS symptoms or disease-related
items¶
3 (0.1) 3 (1.7)
Treatment failure‡ 3 (0.1) 3 (1.7)
Keratitis 3 (0.1) 2 (1.1)
Lymphadenopathy 2 (0.1) 2 (1.1)
Testicular involvement 2 (0.1) 2 (1.1)
Liver disease 2 (0.1) 1 (0.6)
Orbit and sinus wall osteolysis‡ 2 (0.1) 1 (0.6)
Deep venous thrombosis‡ 1 (0.05) 1 (0.6)
Hemorrhagic lesions on palate 1 (0.05) 1 (0.6)
Myocarditis 1 (0.05) 1 (0.6)
Neuropathic pain‡ 1 (0.05) 1 (0.6)
Night sweats 1 (0.05) 1 (0.6)
Pulmonary artery stenosis‡ 1 (0.05) 1 (0.6)
Skull-based mass‡ 1 (0.05) 1 (0.6)
Tinnitus 1 (0.05) 1 (0.6)
* CNS  central nervous system.
† Generic variables combining several other items.
‡ Other items rated as major.
§ Generic variable combining several other items; includes 1 rating
of cricoarytenoid inflammation as major other.
¶ Generic variable combining several other items; includes ratings
of CNS vasculitis and pituitary involvement (each rated once) as
major other.
Table 1. Use of 34 predefined Birmingham Vasculitis
Activity Score for Wegener’s Granulomatosis items in








Arthralgia/arthritis 351 (17.2) 135 (75.0)
Nasal discharge/crusting 331 (16.2) 122 (67.8)
Sinus involvement 199 (9.7) 98 (54.4)
Nodules or cavities 141 (6.9) 67 (37.2)
Hematuria 115 (5.6) 77 (42.8)
Conductive deafness 95 (4.7) 52 (28.9)
Other infiltrates 83 (4.1) 63 (35.0)
Red blood cell casts* 66 (3.2) 58 (32.2)
Subglottic inflammation 54 (2.6) 22 (12.2)
30% creatinine increase* 51 (2.5) 46 (25.6)
Conjunctivitis/episcleritis 47 (2.3) 36 (20.0)
Purpura 43 (2.1) 35 (19.4)
Fever 42 (2.1) 38 (21.1)
Alveolar hemorrhage* 37 (1.8) 35 (19.4)
Mouth ulcers 28 (1.4) 26 (14.4)
Retroorbital mass/proptosis 28 (1.4) 12 (6.7)
Sensorineural deafness* 27 (1.3) 11 (6.1)
Sensory neuropathy* 26 (1.3) 20 (11.1)
Endobronchial involvement 19 (0.9) 11 (6.1)
Pleurisy 18 (0.9) 16 (8.9)
Skin ulcers 17 (0.8) 8 (4.4)
Scleritis* 11 (0.5) 8 (4.4)
Swollen salivary gland 6 (0.3) 6 (3.3)
Motor neuropathy* 6 (0.3) 4 (2.2)
Cranial nerve palsy* 5 (0.2) 5 (2.8)
Respiratory failure* 3 (0.2) 3 (1.7)
Mesenteric ischemia* 2 (0.1) 2 (1.1)
Pericarditis 2 (0.1) 2 (1.1)
Gangrene* 1 (0.1) 1 (0.6)
Uveitis 1 (0.1) 1 (0.6)
Retinal exudates/hemorrhage* 0 (0) 0 (0)
Meningitis* 0 (0) 0 (0)
Cord lesion* 0 (0) 0 (0)
Stroke* 0 (0) 0 (0)
* Major items.
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0.6608; dichotomous (2 or 2): R2  0.6726; 3-level
ordinal (0, 1, or 2): R2  0.6732; dichotomous (3 or 3):
R2  0.6746; 4-level ordinal (0, 1, 2, or 3): R2  0.6796.
Ultimately, we selected the 3-level ordinal format (0, 1, or
2) because this provided a uniformly high fit when ap-
plied to the full data set of 2,026 visits or the 180 visits at
baseline.
The results of the final linear regression model are
shown in Table 3. No substantial changes in these results
were observed in additional analyses, which excluded the
4 BVAS/WG forms with possible outlier PGA values (see
above) or included trial center as a covariate, and by GEE
modeling that controlled for potential data correlation
within trial centers. The variables salivary gland involve-
ment, mouth ulcers, endobronchial disease, and conjunc-
tivitis/episcleritis were dropped from this model because
they yielded negative weights or rounded to zero. When
assigning to these 4 variables a minimal weight of 1, the R2
of the model decreased only slightly to 0.6725. The latter
index will be referred to as the modified BVAS/WG.
Cross-validation. The cross-validation was also based
on the 734 visits with active disease. The weights gener-
ated for the 30 items in any of the derivation models (each
used either four-fifths of the data set or all data except
those from 1 trial center) only marginally differed from the
weights that were produced from the full data set. When
using these derived weighting systems to calculate the
activity scores in the corresponding validation subsample,
Table 3. Results of the linear regression model (based on
734 visits with active disease and using the physician’s
global assessment as the dependent variable and the
Birmingham Vasculitis Activity Score for Wegener’s
Granulomatosis items as explanatory variables) and







coefficient P Original New
Alveolar
hemorrhage
36 20.74  0.0001 3 21
30% creatinine
increase
50 17.39  0.0001 3 17
Sensory
neuropathy
26 16.00  0.0001 3 16
Red blood cell
casts
63 14.81  0.0001 3 15
Weight loss 12 12.89 0.005 NA 13
Fatigue 55 11.48  0.0001 NA 11
Nodules or
cavities
138 10.20  0.0001 1 10
Other infiltrates 81 9.96  0.0001 1 10
Hematuria 111 8.97  0.0001 1 9
Major other 25† 7.54 0.03 3 8
Sensorineural
deafness
27 7.54 0.01 3 8
Cranial nerve
palsy
5 7.04 0.24 3 7
Sinus involvement 196 6.89  0.0001 1 7
Subglottic
inflammation
53 6.28 0.01 1 6
Skin ulcers 17 6.06 0.04 1 6
Pleurisy 18 5.55 0.11 1 6
Purpura 41 5.03 0.03 1 5
Scleritis 11 4.29 0.22 3 4
Retroorbital mass/
proptosis
27 3.95 0.21 1 4
Motor neuropathy 6 3.75 0.52 3 4
Nasal discharge/
crusting
327 3.19 0.01 1 3
Minor other 89‡ 3.17 0.06 1 3
Arthralgia/arthritis 339 2.51 0.05 1 3
Fever 41 2.36 0.29 1 2
Conductive
deafness
93 1.94 0.24 1 2
Conjunctivitis/
episcleritis
45 0.07 0.98 1 1§
Endobronchial
involvement
18 – – 1 1§
Mouth ulcers 28 – – 1 1§
Salivary gland
involvement
6 – – 1 1§
New/worse¶
1 item 140 6.46  0.0001 NA 6
2 items 303 15.09  0.0001 NA 15
* Except for the new/worse item, variables are sorted from highest
to lowest new weights. No.  total number of ratings of explanatory
variables; NA  not applicable.
† Accounting for 23 visits.
‡ Accounting for 75 visits.
§ Variables with negative regression coefficients in the regression
model or values rounded to 0 that were assigned a weight of 1.
¶ Visit with 1 item rated new/worse.
Figure 1. Summary flow diagram of Birmingham Vasculitis Ac-
tivity Score for Wegener’s Granulomatosis (BVAS/WG) items im-
plemented in the linear regression models used to derive a new
item weighting system (R2 values refer to the model’s ability to
predict the physician’s global assessment of disease activity).
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the R2 to predict the PGA within the reassembled full data
set was only slightly lower than the R2 obtained by the full
model: 0.6444 (for the first approach that split the data set
into 5 random subsets) and 0.6194 (for the second ap-
proach of data partitioning according to trial centers), re-
spectively. Therefore, the cross-validation findings sug-
gested replicability of both the generated item weights and
the increased ability of the modified BVAS/WG to explain
the PGA.
Performance characteristics of the modified BVAS/WG.
The modified BVAS/WG had item weights ranging from 1
to 21 (Table 3). The possible range of scores was 0 to 204,
plus other items.
Figure 2 shows the observed distributions of scores of
the modified BVAS/WG as compared with the original
BVAS/WG and a completely unweighted BVAS/WG for
the 734 visits with active disease. Mean  SD scores were
24.1  20.4 (range 0–108) for the modified BVAS/WG,
3.4  3.0 (range 0–17) for the original BVAS/WG, and
2.7  2.0 (range 0–12) for the unweighted BVAS/WG. For
the 180 trial participants at baseline (study entry), the
mean modified BVAS/WG, original BVAS/WG, and un-
weighted BVAS/WG scores were 49.6  19.1 (range 10–
108), 6.9  3.4 (range 2–17), and 5.0  2.1 (range 1–12),
respectively.
Table 4 shows the correlation coefficients of the PGA
with these 3 scores for all 734 visits with active disease,
Figure 2. Distributions and scatter plots (plotted against the physician’s global assessment [PGA]) of the disease activity scores for the
modified Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG), original BVAS/WG, and unweighted
BVAS/WG based on 734 trial visits assessing active Wegener’s granulomatosis (i.e., PGA 0).
Table 4. Pearson’s correlation coefficients of the modified Birmingham Vasculitis
Activity Score for Wegener’s Granulomatosis (BVAS/WG), original BVAS/WG, and




All active visits 734 0.82† 0.75† 0.73†  0.0001
Limited WG‡ 277 0.79† 0.65† 0.67†  0.0001
Severe WG‡ 457 0.82† 0.78† 0.75†  0.0001
Baseline visits 180 0.71† 0.62† 0.51†  0.0001
Limited WG 52 0.66† 0.45§ 0.46§  0.005
Severe WG 128 0.68† 0.58† 0.49† 0.0005
All visits 2,026 0.90† 0.87† 0.86†  0.0001
* For comparisons of correlation coefficients of modified BVAS/WG and BVAS/WG (as originally re-
ported) calculated by Hotelling’s statistics (9).
† P  0.0001.
‡ According to WG disease classification as determined at study entry.
§ P  0.001.
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the 180 baseline visits, and all 2,026 visits with com-
plete BVAS/WG information. Predictably, the modified
BVAS/WG correlated more strongly with the PGA than the
original BVAS/WG or the unweighted BVAS/WG. Analy-
ses stratified by disease pattern indicated more substantial
differences among patients originally classified as having
limited as opposed to severe WG. In all subsets, the differ-
ences between the correlation coefficients of the modified
BVAS/WG and the original BVAS/WG were statistically
significant (P  0.005).
DISCUSSION
We reevaluated the BVAS/WG using a data-driven ap-
proach. Our results suggest possible ways to enhance the
item selection and weighting of the instrument that could
improve performance characteristics substantially. When
expressed as the ability (R2) to predict the PGA for disease
activity, these modifications increased the R2 from 57% for
the original BVAS/WG to 67% for the modified BVAS/WG,
a sizeable difference when considering that a completely
unweighted BVAS/WG yielded a value of 53%. Cross-
validation demonstrated that our findings were internally
replicable and generalizable across the various centers in-
volved in the study.
The content validity of the BVAS/WG relies in large part
on the comprehensiveness of the list of predefined disease
descriptors to ensure that manifestations most pertinent to
disease activity assessment are rated consistently. Our
findings indicate that fatigue and weight loss should be
included as specific items, because both were added fre-
quently as other items and because they improve the in-
strument’s ability to predict the PGA. The weights of 11
and 13 generated for these 2 variables emphasize that
physicians highly value constitutional symptoms as indi-
cators of disease activity in patients with WG. The great
variety of the remaining other manifestations (Table 2)
reflects the protean nature of WG, and the weights gener-
ated for the pooled minor other and major other categories
underscore the utility of accommodating and counting
unlisted manifestations. In contrast, 9 predefined items
that refer to less common features of WG were used in 5
visits, suggesting that the BVAS/WG item list could be
streamlined without resulting in untoward effects.
The PGA of disease activity included in the BVAS/WG
form provided an unprecedented opportunity to compute
an item weighting system. The calculated range of weights
of 1–21 cover a much broader spectrum than the original,
expert opinion-based weights used in either the BVAS/WG
(weights 1 or 3) (1) or its precursor, the BVAS (weights
1–9) (2). In addition, the new weights add substantially to
the ability of the index to explain the PGA and appear to
have face validity. Indeed, alveolar hemorrhage, items re-
lated to renal disease, and sensory neuropathy were the
highest ranked weights, and major other items were ranked
higher than minor other items.
Although the generated weights offer new insight into
the extent to which individual features of WG contribute
to physicians’ perception of overall disease activity, they
must be interpreted with several caveats. First, the esti-
mates of some infrequently rated items may lack precision,
as suggested by nonsignificant P values of the beta coeffi-
cients. Also, as is common in multiple regression models,
the accuracy of the estimates may have been hampered by
collinearity between variables. However, bivariate analy-
ses among all explanatory variables did not detect corre-
lations exceeding 0.40 (results not shown), suggesting that
collinearity was not a major issue. A slightly different
situation occurs for manifestations that seldom (or never)
present in isolation, and whose assigned weights are there-
fore connected to weights of related items. Motor neurop-
athy, for example, was assigned a seemingly low weight of
4, but this manifestation was scored concomitantly with
sensory neuropathy in all cases except one, thereby con-
tributing to a combined weight of 20 for the variable sen-
sory-motor neuropathy.
An additional significant finding pertains to the new/
worse item, a newly created variable that informed whether
1 or several manifestations had been rated as new/worse at
a given visit. It is well acknowledged that once treated,
patients with WG may undergo a substantial and durable
improvement without achieving remission. In terms of
disease activity scoring, this is a tricky problem in that
persistent manifestations likely reflect a lower level of
disease activity. Pertinently, our data demonstrate that
physicians’ ratings of disease activity were independently
higher when new/worse manifestations were present and
suggest that such a weighted new/worse variable may con-
stitute a valuable means to take account of the different
disease activity levels of new/worsening and persistent
WG. Our findings further indicate that different levels of
gradation exist for this variable: visits associated with 1 or
2 new/worse items were assigned weights of 6 and 15,
respectively. Whether more widespread gradations within
variables (accounting for different intensities of clinical
manifestations) could further improve the performance of
the BVAS/WG is beyond the scope of this study.
The present findings have a number of important impli-
cations. Owing to the enhanced item selection, the imple-
mentation of a data-derived weighting system, and the
addition of a new/worse variable, the modified BVAS/WG
may have greater ability to capture the continuum of dis-
ease activity in patients with WG. The modified BVAS/WG
could permit more accurate comparisons of the absolute
scores across patients and more precise measurements
of the relative amount in disease activity changes at dif-
ferent time points. Such a modified scale could also facil-
itate the translation of BVAS/WG scores into specific states
of disease activity. In particular, there is a recognized need
to delineate the state of “grumbling,” low-level disease
activity that may be a possible therapeutic target in clinical
trials.
Our study has several strengths. This analysis took ad-
vantage of a large, prospectively collected data set. Be-
cause the data set was derived from participants in a
multicenter clinical trial with broad eligibility criteria, our
results are extrapolated more easily to clinical settings
compared with alternative study designs that might have
been used, such as investigations based on written sum-
maries of hypothetical patients or a convenience sample of
real patients from only 1 center. Moreover, the trial in-
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volved 8 centers with expertise in WG and investigators
previously trained to use the BVAS/WG, thereby ensuring
a high quality in the BVAS/WG assessments and PGA
ratings. The consistency in PGA ratings was also indicated
by our observation that adjustment of the regression for the
trial centers did not affect the values of the derived item
weights substantially.
There are 2 factors, both related to the PGA, that poten-
tially limit our findings. First, although the BVAS/WG was
originally validated against the PGA (1), one may question
the use of the PGA as a reference value to derive the new
item weights and to evaluate the modified BVAS/WG.
Nonetheless, because there is no other current gold stan-
dard for the assessment of disease activity in WG, the
PGA represents the most suitable universal means for
quantifying WG activity. Of note, the PGA has also been
selected as a core set measure for disease activity assess-
ment in a number of other rheumatic diseases (11–14).
Second, it could be claimed that because they were not
performed independently, the PGA ratings simply repro-
duced the scores reached by the BVAS/WG. However, this
possibility seems countered by the substantial differences
between the original and modified item weights and the
apparently reasonable weights generated for the newly
implemented new/worse variable.
In conclusion, this study clarifies the selection and
weighting of the clinical features that are most relevant to
measure disease activity in patients with WG. The pro-
posed modifications should be considered for further eval-
uation and use in clinical research and viewed as a stage in
the iterative process of refining the BVAS/WG and perhaps
other related instruments.
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patrick, Ken Fye, Steve Lund (University of California, San
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(University of Michigan); Noel R. Rose, C. Lynne Burek,
Jobert Barin, Monica Talor (The Johns Hopkins University
Immune Diseases Laboratory); Paul L. Canner (Maryland
Medical Research Institute); Doyt L. Conn (Emory Univer-
sity); Jack H. Klippel (Arthritis Foundation); J. Richard
Landis (University of Pennsylvania).
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